Overview

Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and safety of ATV/r at either 200/100 mg or 300/100mg given daily in Thai patients in combination with 2NRTIs.
Phase:
Phase 4
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators:
Kirby Institute
National Health Security Office, Thailand
Treatments:
Atazanavir Sulfate
Ritonavir